Impact of Long-Acting Calcium Channel Blockers on the Prognosis of Patients with Coronary Artery Disease with and without Chronic Kidney Disease: A Comparison of Three Drugs
Free accessResearch articleFirst published online February, 2010
Impact of Long-Acting Calcium Channel Blockers on the Prognosis of Patients with Coronary Artery Disease with and without Chronic Kidney Disease: A Comparison of Three Drugs
Calcium channel blockers (CCBs) can prevent cardiovascular events in patients with coronary artery disease (CAD). This study looked retrospectively at the prognosis of CAD in hypertensive patients with CAD who had undergone a coronary angiograph, had been given a CCB (benidipine [n = 66], amlodipine [n = 45], or long-acting nifedipine [n = 31]) on hospital discharge and were then followed up for a mean ± SD of 5.2 ± 2.9 years. Systolic/diastolic blood pressure for all 142 patients decreased significantly from a mean ± SD of 137 ± 20/74 ± 15 mmHg to 129 ± 20/71 ± 12 mmHg. Major adverse cardiovascular events (MACE) occurred in 15 patients. Chronic kidney disease (CKD) was a significant risk factor for MACE (hazard ratio 2.35, 95% confidence intervals 1.45, 3.80). Benidipine was superior to nifedipine in preventing MACE in patients both with and without CKD. In conclusion, benidipine and amlodipine reduced the frequency of MACE in hypertensive patients with CAD, particularly in those with complicating CKD.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002; 288: 2981–2997.
2.
JuliusSKjeldsenSEWeberM: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet2004; 363: 2022–2031.
3.
NissenSETuzcuEMLibby P, et al for the CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: A randomized controlled trial. JAMA2004; 292: 2217–2225.
4.
WalterMFJacobRFBjork RE, et al for the PREVENT Investigators: Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: The PREVENT study. J Am Coll Cardiol2008; 51: 1196–1202.
5.
YuiYShinodaEKodama K, et al for the Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group: Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens2007; 25: 2019–2026.
6.
PepineCJHandbergEMCooper-DeHoff RM et al for the INVEST Investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA2003; 290: 2805–2816.
7.
MaseriABeltrameJFShimokawaH: Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J2009; 73: 394–403.
8.
ShimokawaHNagasawaKIrieT: Clinical characteristics and long-term prognosis of patients with variant angina. A comparative study between Western and Japanese populations. Int J Cardiol1988; 18: 331–349.
9.
YamagishiMItoKTsutsuiH: Lesion severity and hypercholesterolemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J2003; 67: 1029–1035.
10.
ItoAFukumotoYShimokawaH: Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol2004; 44: 480–485.
11.
IoKMinatoguchiSNishigakiK: Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test. Arzneimittelforschung2007; 57: 573–581.
12.
FukumotoYYasudaSItoA: Prognostic effects of benidipine in patients with vasospastic angina: Comparison with diltiazem and amlodipine. J Cardiovasc Pharmacol2008; 51: 253–257.
13.
AustenWGEdwardsJEFryeRL: A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation1975; 51 (4 suppl): 5–40.
14.
OgiharaTKikuchiKMatsuoka H, et al for the Japanese Society of Hypertension (JSH) Committee: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res2009; 32: 3–107.
15.
MatsuoSImaiEHorioM: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis2009; 53: 982–992.
16.
NinomiyaTKiyoharaYKuboM: Chronic kidney disease and cardiovascular disease in a general Japanese population: The Hisayama Study. Kidney Int2005; 68: 228–236.
17.
TaniwaTMiyatakaMKimuraA: Calcium antagonists for secondary prevention of myocardial infarction: Is there a need to shift from short-acting to long-acting types?Circ J2005; 69: 1308–1314.
18.
AldermanMHCohenHRoquéR: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet1997; 349: 594–598.
19.
KarasawaAKuboK: Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol1988; 47: 35–44.
20.
ShimadaSNakajimaYYamamotoK: Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biol Pharm Bull1996; 19: 430–437.
21.
KarasawaANomuraHNitoM: Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats. Nippon Yakurigaku Zasshi1999; 113: 317–326 [in Japanese].
22.
AkizukiOInayoshiAKitayamaT: Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol2008; 584: 424–434.
23.
MatsubaraMYaoKHasegawaK: Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release. Pharmacol Res2006; 53: 35–43.
24.
YaoKInaYNagashimaK: Antioxidant effects of calcium antagonists in rat brain homogenates. Biol Pharm Bull2000; 23: 766–769.
